Sign In
Buy OVID
$2.40
-0.0800 (-3.23%)
At Close: Jun 05, 2026
Ovid Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Thursday, 04'th Jun 2026
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant un
Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors
07:00am, Wednesday, 03'rd Jun 2026
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant un
Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
07:00am, Tuesday, 12'th May 2026
Dosed first participant with OV4071, the first-ever oral potassium-chloride cotransporter 2 (KCC2) direct activator, in May 2026 in a Phase 1 study with healthy volunteers OV329 showed favorable safet
AtaiBeckley wins OVID Health Silver Award for patient partnership in psychedelic trials
08:36am, Monday, 27'th Apr 2026
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) said on Monday it had received the Silver Award in OVID Health's 2026 Patient Participant Index, recognizing its collaboration with the Psychedelic Participan
Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transcript
06:41pm, Tuesday, 14'th Apr 2026
Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transcript
Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14
08:00am, Wednesday, 08'th Apr 2026
NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, tod
Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Recommendation of “Buy” from Brokerages
02:50am, Thursday, 26'th Mar 2026
Shares of Ovid Therapeutics (NASDAQ: OVID - Get Free Report) have received an average rating of "Buy" from the nine research firms that are currently covering the company, Marketbeat Ratings reports.
Ovid Therapeutics: Seizing The Moment With Phase 2 Ready Assets And PIPE Funding
07:45am, Friday, 20'th Mar 2026
Ovid Therapeutics advances OV329, a GABA-AT inhibitor, into Phase 2 for drug-resistant adult focal onset seizures after soticlestat's failure. Recent Phase 1 data show OV329 lacks the eye toxicity see
Ovid Therapeutics Inc. (OVID) Q4 2025 Earnings Call Transcript
05:02pm, Wednesday, 18'th Mar 2026
Ovid Therapeutics Inc. (OVID) Q4 2025 Earnings Call Transcript
Here's Why Ovid Therapeutics Stock Popped Higher Today
02:17pm, Wednesday, 18'th Mar 2026
OV329 may be safer and more potent than existing treatments. A $60M private placement will fund further development.
Ovid Therapeutics' New Epilepsy Trial Data Ignites Rally
10:01am, Wednesday, 18'th Mar 2026
Ovid Therapeutics reported favorable topline safety and tolerability findings from a 7 mg dose cohort of OV329 for drug-resistant epilepsies.
Ovid Therapeutics (OVID) Q4 Earnings and Revenues Surpass Estimates
08:51am, Wednesday, 18'th Mar 2026
Ovid Therapeutics (OVID) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.1 per share. This compares to a loss of $0.13 per share a year ago.
NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, tod
Ovid Therapeutics Announces Pricing of $60 Million Private Placement
06:00am, Wednesday, 18'th Mar 2026
NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, tod
Ovid Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Wednesday, 25'th Feb 2026
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines to treat brain disorders and symptoms caused by exces
